Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs NIO Inc. — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.3 (market cap $12.58B), while NIO Inc. trades at $3.58 (market cap $8.62B). The key difference: Halozyme Therapeutics Inc. Common Stock is the larger of the two by market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and NIO Inc. for 81 Days on average.
| HALO | NIO | |
|---|---|---|
Market Cap | $12.58B | $8.62B |
Volume | 2,179,278 | 39,648,517 |
Sector | Health | Consumer Cyclical |
52-Week High | $115.22 | $7.46 |
52-Week Low | $61.63 | $3.37 |
Typical Hold Time | 0 Days | 81 Days |
Enterprise Value | $14.49B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NIO trades at $3.60, up 1.69% today but near 52-week lows, with technical indicators showing bearish momentum. The company reported Q3 2026 deliveries up 25.4% and recently completed a strategic battery-swapping partnership with Geely. Despite revenue growth to $87.49B in 2025, NIO continues to post significant losses with a -17.8% net margin. Analyst consensus remains positive with a $6.23 price target, though technical signals and cash flow challenges present headwinds.
NIO's growth trajectory and strategic partnerships offer long-term potential, but investors face substantial execution risks amid persistent losses and competitive pressures. The stock's current discount to analyst targets presents opportunity, but requires careful monitoring of profitability improvements and market share sustainability in the crowded EV sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
